IL229227A0 - Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof - Google Patents

Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof

Info

Publication number
IL229227A0
IL229227A0 IL229227A IL22922713A IL229227A0 IL 229227 A0 IL229227 A0 IL 229227A0 IL 229227 A IL229227 A IL 229227A IL 22922713 A IL22922713 A IL 22922713A IL 229227 A0 IL229227 A0 IL 229227A0
Authority
IL
Israel
Prior art keywords
compositions
same
oligonucleotide conjugates
peptide oligonucleotide
peptide
Prior art date
Application number
IL229227A
Other languages
Hebrew (he)
Other versions
IL229227B (en
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/101,942 external-priority patent/US20110269665A1/en
Priority claimed from US13/107,528 external-priority patent/US9238042B2/en
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of IL229227A0 publication Critical patent/IL229227A0/en
Publication of IL229227B publication Critical patent/IL229227B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL229227A 2011-05-05 2013-11-04 Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof IL229227B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/101,942 US20110269665A1 (en) 2009-06-26 2011-05-05 Compound and method for treating myotonic dystrophy
US13/107,528 US9238042B2 (en) 2010-05-13 2011-05-13 Antisense modulation of interleukins 17 and 23 signaling
PCT/US2011/061282 WO2012150960A1 (en) 2011-05-05 2011-11-17 Peptide oligonucleotide conjugates

Publications (2)

Publication Number Publication Date
IL229227A0 true IL229227A0 (en) 2014-01-30
IL229227B IL229227B (en) 2020-07-30

Family

ID=45218873

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273838A IL273838B (en) 2011-05-05 2011-11-17 Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof
IL229227A IL229227B (en) 2011-05-05 2013-11-04 Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL273838A IL273838B (en) 2011-05-05 2011-11-17 Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof

Country Status (8)

Country Link
EP (1) EP2704749A1 (en)
JP (6) JP6478632B2 (en)
KR (3) KR102339196B1 (en)
CN (2) CN103619356B (en)
AU (5) AU2011367230B2 (en)
CA (2) CA3092114A1 (en)
IL (2) IL273838B (en)
WO (1) WO2012150960A1 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1766010T3 (en) 2004-06-28 2011-06-06 Univ Western Australia Antisense oligonucleotides for inducing exon skipping and methods for their use
ES2852549T3 (en) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Antisense composition for treatment of muscle atrophy
CA2660523C (en) 2006-08-11 2019-03-19 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
HUE028662T2 (en) 2007-10-26 2016-12-28 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
TR201902952T4 (en) 2008-10-24 2019-03-21 Sarepta Therapeutics Inc Exon jump combinations for dmd.
KR102366851B1 (en) 2009-11-12 2022-02-23 더 유니버시티 오브 웨스턴 오스트레일리아 Antisense Molecules and Methods for Treating Pathologies
TWI541024B (en) 2010-09-01 2016-07-11 日本新藥股份有限公司 Antisense nucleic acid
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR20140097398A (en) * 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 Functionally-modified oligonucleotides and subunits thereof
US10066228B2 (en) 2011-11-30 2018-09-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
EP2785840B8 (en) 2011-11-30 2019-05-22 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
LT2788487T (en) 2011-12-08 2018-09-10 Sarepta Therapeutics, Inc. Oligonucleotide analogues targeting human lmna
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
SI2841578T1 (en) 2012-04-23 2017-12-29 Biomarin Technologies B.V. RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
JP2016502858A (en) 2012-12-20 2016-02-01 サレプタ セラピューティクス， インコーポレイテッド Improved exon skipping composition for treating muscular dystrophy
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
WO2014153220A2 (en) * 2013-03-14 2014-09-25 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
LT2970964T (en) 2013-03-14 2019-04-25 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
EP3015467A4 (en) 2013-05-24 2016-11-02 Ajinomoto Kk Morpholino oligonucleotide manufacturing method
AU2014317961B2 (en) * 2013-09-05 2020-07-30 Murdoch University Antisense-induced exon2 inclusion in acid alpha-glucosidase
ES2818073T3 (en) 2013-12-24 2021-04-09 Sentiss Pharma Private Ltd Topical Brimonidine Tartrate Ophthalmic Solution
RU2702424C2 (en) * 2014-03-12 2019-10-08 Ниппон Синяку Ко., Лтд. Antisense nucleic acids
KR101661277B1 (en) * 2014-03-17 2016-09-30 제주광어주식회사 Single point nucleotide changed Live Attenuated Viral Hemorrhagic Septicemia Virus
CA2948373A1 (en) 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
CA2948568A1 (en) 2014-05-19 2015-11-26 David Greenberg Antisense antibacterial compounds and methods
AU2015372560B2 (en) 2014-12-31 2021-12-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
MX2017011004A (en) * 2015-02-27 2018-02-09 Sarepta Therapeutics Inc Antisense-induced exon2 inclusion in acid alpha-glucosidase.
MA41795A (en) * 2015-03-18 2018-01-23 Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
KR20240035901A (en) * 2015-05-19 2024-03-18 사렙타 쎄러퓨틱스 인코퍼레이티드 Peptide oligonucleotide conjugates
EP3302497A4 (en) 2015-06-01 2019-01-16 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type vii collagen
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Methods and compounds for treatment of lymphocyte-related diseases and conditions
UA123995C2 (en) * 2015-08-05 2021-07-07 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Chiral reagents for preparation of homogeneous oligomers
US10905709B2 (en) * 2015-08-28 2021-02-02 Sarepta Therapeutics, Inc. Modified antisense oligomers for exon inclusion in spinal muscular atrophy
KR101841241B1 (en) * 2015-09-10 2018-03-22 한양대학교 산학협력단 fusion peptides associated with inflammatory skin disease and phamaceutical composition comprising the same
EP3359668A4 (en) 2015-10-09 2019-06-05 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
GB2545898B (en) * 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
JP7393121B2 (en) 2015-12-23 2023-12-06 オレゴン ステイト ユニバーシティー Antisense antibacterial compounds and methods
CA3010084A1 (en) 2015-12-23 2017-06-29 Oregon State University Antisense antibacterial compounds and methods
EP3445405A4 (en) * 2016-04-18 2019-12-18 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
BR112018072279A2 (en) * 2016-04-29 2019-02-12 Sarepta Therapeutics, Inc. oligonucleotide analogues targeting human lmna
CA3024153A1 (en) * 2016-06-30 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
CA3025575A1 (en) * 2016-06-30 2018-01-04 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
IL267246B2 (en) 2016-12-19 2023-03-01 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
KR102639633B1 (en) * 2016-12-19 2024-02-26 사렙타 쎄러퓨틱스 인코퍼레이티드 Exon-skipping oligomeric conjugates for muscular dystrophy
NZ755416A (en) 2016-12-19 2023-05-26 Sarepta Therapeutics Inc Exon skipping oligomer conjugates for muscular dystrophy
TW201919682A (en) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 Novel compounds activating the Nrf2 pathway
EA201991450A1 (en) * 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
EP3684933A4 (en) * 2017-09-22 2021-06-23 The Regents of the University of Colorado, A Body Corporate Thiomorpholino oligonucleotides for the treatment of muscular dystrophy
WO2019067975A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
WO2019067981A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
EP3687519A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
EP3697422A4 (en) * 2017-10-17 2021-08-11 Sarepta Therapeutics, Inc. Cell-penetrating peptides for antisense delivery
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
EP3784248A4 (en) * 2018-04-26 2022-08-10 Sarepta Therapeutics, Inc. Exon skipping oligomers and oligomer conjugates for muscular dystrophy
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
US20220251551A1 (en) * 2018-06-13 2022-08-11 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
TW202020153A (en) 2018-07-27 2020-06-01 美商薩羅塔治療公司 Exon skipping oligomers for muscular dystrophy
EP3829597A4 (en) * 2018-07-30 2022-05-18 Sarepta Therapeutics, Inc. Trimeric peptides for antisense delivery
GB201812980D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
WO2020115494A1 (en) * 2018-12-07 2020-06-11 Oxford University Innovation Limited Linkers
EP3894558A1 (en) 2018-12-13 2021-10-20 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
US20220193246A1 (en) 2019-04-18 2022-06-23 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
CN110724180B (en) * 2019-10-17 2021-08-20 山东大学 Polypeptide for inhibiting angiogenesis and application thereof
CN114901823A (en) 2019-12-26 2022-08-12 日本新药株式会社 Antisense nucleic acids inducing skipping of exon 50
AU2021224412A1 (en) 2020-02-22 2022-09-15 Jcr Pharmaceuticals Co., Ltd. Human transferrin receptor binding peptide
KR20220145865A (en) 2020-02-28 2022-10-31 니뽄 신야쿠 가부시키가이샤 Antisense nucleic acid that induces skipping of exon 51
KR20220148230A (en) 2020-02-28 2022-11-04 아이오니스 파마수티컬즈, 인코포레이티드 Compounds and methods for modulating SMN2
US20240024414A1 (en) * 2020-09-21 2024-01-25 Icahn School Of Medicine At Mount Sinai Archaea l30 proteins as universal influenza virus therapeutics
WO2022140535A1 (en) 2020-12-23 2022-06-30 Sarepta Therapeutics, Inc. Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
WO2022171972A1 (en) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
WO2022232478A1 (en) 2021-04-30 2022-11-03 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
TW202307208A (en) 2021-06-23 2023-02-16 日商日本新藥股份有限公司 Combination of antisense oligomers
TW202308664A (en) 2021-07-08 2023-03-01 日商日本新藥股份有限公司 Nephrotoxicity-reducing agent
WO2023282345A1 (en) 2021-07-08 2023-01-12 日本新薬株式会社 Nephrotoxicity reducing agent
AU2022306542A1 (en) 2021-07-08 2024-01-18 Nippon Shinyaku Co., Ltd. Precipitation suppressing agent
WO2023026994A1 (en) 2021-08-21 2023-03-02 武田薬品工業株式会社 Human transferrin receptor binding peptide-drug conjugate
CA3229962A1 (en) 2021-08-24 2023-03-02 Peptidream Inc. Human transferrin receptor-binding antibody-peptide conjugate
WO2023055774A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
WO2023178230A1 (en) 2022-03-17 2023-09-21 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency
WO2024097822A1 (en) 2022-11-02 2024-05-10 Sarepta Therapeutics, Inc. Formulation of an antisense oligomer conjugate

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
ATE171185T1 (en) 1985-03-15 1998-10-15 Antivirals Inc POLYNUCLEOTIDE IMMUNOTESTING AGENTS AND METHODS
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
WO1993001286A2 (en) 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
DK0656950T3 (en) 1992-08-21 1999-07-19 Biogen Inc TAT-derived transport polypeptides
JPH0915828A (en) 1995-07-03 1997-01-17 Fuji Photo Film Co Ltd Paper cutter for photographic processing system
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
BR9809138A (en) 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugate and method to increase the transport of a selected compound across a biological membrane
WO1999005302A1 (en) * 1997-07-24 1999-02-04 The Perkin-Elmer Corporation Conjugates of transporter peptides and nucleic acid analogs, and their use
DE19933492B4 (en) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Conjugate for the mediation of a cell-, compartment- or membrane-specific transport of active substances, process for its preparation and its use
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
DE60233137D1 (en) 2001-02-16 2009-09-10 Univ R TRANSPORTER WITH FILLED ARGININE PARTICLES
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
WO2004097017A2 (en) 2003-04-29 2004-11-11 Avi Biopharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
WO2005030800A2 (en) 2003-08-05 2005-04-07 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
MXPA06012605A (en) * 2004-05-04 2006-12-15 Nastech Pharm Co Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells.
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
DK1766010T3 (en) 2004-06-28 2011-06-06 Univ Western Australia Antisense oligonucleotides for inducing exon skipping and methods for their use
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
ES2852549T3 (en) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Antisense composition for treatment of muscle atrophy
EP3470072A1 (en) 2005-06-23 2019-04-17 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing
AU2006287530A1 (en) 2005-09-08 2007-03-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007030691A2 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US7582615B2 (en) 2006-03-07 2009-09-01 Avi Biopharma, Inc. Antisense antiviral compound and method for treating arenavirus infection
SI2735568T1 (en) 2006-05-10 2018-01-31 Sarepta Therapeutics, Inc. Oligonucleotide analogs having cationic intersubunit linkages
CA2660523C (en) 2006-08-11 2019-03-19 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
EP2560001B1 (en) 2006-09-21 2016-04-13 University of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
JP5227803B2 (en) 2006-11-24 2013-07-03 ハイクス ラボラトリーズ合同会社 Spiroquinone compounds and pharmaceutical compositions
WO2009005783A1 (en) * 2007-06-28 2009-01-08 Blanchette Rockefeller Neurosciences Institute Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
AU2008271050B2 (en) * 2007-06-29 2014-11-06 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
CN101861318A (en) 2007-11-15 2010-10-13 Avi生物制药公司 Method of synthesis of morpholino oligomers
RU2010129761A (en) * 2007-12-20 2012-01-27 Ангиочем Инк. (Ca) Nucleic Acid Polypeptides Conjugates and Their Use
WO2009144481A2 (en) * 2008-05-30 2009-12-03 Isis Innovation Limited Conjugates for delivery of biologically active compounds
TR201902952T4 (en) 2008-10-24 2019-03-21 Sarepta Therapeutics Inc Exon jump combinations for dmd.
WO2010072228A1 (en) * 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2010120820A1 (en) 2009-04-13 2010-10-21 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing
KR20190037378A (en) 2009-06-17 2019-04-05 바이오젠 엠에이 인코포레이티드 Composition and methods for modulating of smn2 splicing in a subject
ES2816898T3 (en) * 2010-05-13 2021-04-06 Sarepta Therapeutics Inc Compounds that modulate the signaling activity of interleukins 17 and 23

Also Published As

Publication number Publication date
WO2012150960A1 (en) 2012-11-08
AU2011367230A1 (en) 2013-12-05
CN107693797B (en) 2021-05-11
KR102229650B1 (en) 2021-03-19
JP2014515762A (en) 2014-07-03
CN107693797A (en) 2018-02-16
JP6884250B2 (en) 2021-06-09
AU2023203112A1 (en) 2023-06-08
JP2020111607A (en) 2020-07-27
AU2011367230B2 (en) 2017-08-10
AU2019204913A1 (en) 2019-07-25
CN103619356B (en) 2017-09-12
CN103619356A (en) 2014-03-05
CA2834128A1 (en) 2012-11-08
AU2017206179A1 (en) 2017-08-03
KR102183273B1 (en) 2020-11-27
KR20210032545A (en) 2021-03-24
KR102339196B1 (en) 2021-12-15
EP2704749A1 (en) 2014-03-12
IL273838B (en) 2022-09-01
JP6478632B2 (en) 2019-03-06
JP2024032974A (en) 2024-03-12
AU2021202224A1 (en) 2021-05-06
IL229227B (en) 2020-07-30
KR20190084351A (en) 2019-07-16
IL273838A (en) 2020-05-31
KR20140028058A (en) 2014-03-07
JP2016185991A (en) 2016-10-27
CA3092114A1 (en) 2012-11-08
JP2021113232A (en) 2021-08-05
JP2018135396A (en) 2018-08-30

Similar Documents

Publication Publication Date Title
IL273838A (en) Peptide oligonucleotide conjugates ,compositions comprising the same and uses thereof
IL279304A (en) Cytotoxic benzodiazepine derivatives, compositions comprising the same and uses thereof
IL256921A (en) Pyrazolopyrimidines, pharmaceutical compositions comprising thereof and uses thereof
IL233154A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
IL252154A0 (en) Anti-dr5 antibodies, compositions comprising the same and uses thereof
IL236348A0 (en) Anti-jagged antibodies, compositions comprising the same and uses thereof
IL220283A0 (en) 4-oxo-ih-quinoline-3- carboxamides, compositions comprising the same and uses thereof
IL237625A0 (en) Anti-mcam antibodies, compositions comprising same and uses thereof
IL228715A0 (en) Aminopyrazine compounds ,compositions comprising the same and uses thereof
IL226383B (en) Anti-ccl20 antibodies, compositions comprising the same and uses thereof
IL233934B (en) Cd47 antibodies, compositions comprising the same and uses thereof
IL223361A (en) Purinone derivatives, compositions comprising the same and uses thereof
EP2646539A4 (en) Durable styling compositions and the uses thereof
IL228322A0 (en) Dispiropyrrolidine derivatives compositions comprising the same and uses thereof
IL216254A (en) Compounds, pharmaceutical compositions comprising the same and uses thereof
PL2588556T3 (en) Composition comprising 2,3,3,3-tetrafluoropropene
IL225460B (en) Antibodies binding 191p4d12, compositions comprising the same and uses thereof
PL2590916T3 (en) Stable 2,3,3,3-tetrafluoropropene composition
IL235004A0 (en) Anti-fgfr2 antibodies, compositions comprising same and uses thereof
IL223405B (en) Phosphaplatins, compositions comprising the same and uses thereof
HK1182934A1 (en) Anti-fatigue composition, formulation and use thereof
IL219243A (en) 5-hydroxypyrimidine-4-carboxamide derivatives, compositions comprising the same and uses thereof
IL227705A0 (en) Topical antifungal agent, compositions comprising the same and uses thereof
IL232383B (en) Anti-kdr antibodies, compositions comprising same and uses thereof
IL225464B (en) Nd2 peptides, compositions comprising the same and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed